Latest news

Orchard Therapeutics announces today an alliance with PharmaCell B.V. (“PharmaCell”), a leading Contract Manufacturing Organization (CMO) for Cell and Gene Therapies and Regenerative Medicine.

Orchard Therapeutics announces today that it has entered into a strategic alliance with Oxford BioMedica plc, a world-leading company in gene and cell therapy.

Orchard Therapeutics Limited and researchers from the UCLA Broad Stem Cell Research Center, led by Orchard Scientific Advisory Board member Dr. Donald Kohn have been awarded $20 million by the California Institute for Regenerative Medicine’s governing board (CIRM).